Identifying robust survival subgroups of hepatocellular carcinoma (HCC) will significantly improve patient care.
Introduction
Hepatocellular carcinoma (HCC) is the most prevalent type (70-90%) of liver cancer, and 2 nd leading cancer responsible for the mortality in men 1 . In USA, it has the 2 nd highest incidence rate and highest mortality rate 2 .
HCC is aggravated by various risk factors, including HBV/HCV infection, nonalcoholic steatohepatitis (NASH), alcoholism, and smoking. These confounding factors along with high level of heterogeneity have rendered HCC prognosis a much challenging task 3, 4 . HCC is a detrimental disease with poor prognosis in general, where median survival is less than 2 years 5 . In particular, 5-year survival rate of HBV-associated HCC is less than 30% in multiple studies [5] [6] [7] [8] . Treatment strategies in HCC are very limited, imposing additional urgent needs for developing tools to predict patient survival 9 .
To understand the HCC heterogeneity among patients, a considerable amount of work has been done to identify the HCC molecular subtypes [10] [11] [12] [13] [14] [15] [16] . A variety of numbers of subtypes were identified, ranging from 2 to 6, based on various omics data types, driving hypotheses and computational methods. Besides most commonly used mRNA gene expression data, a recent study integrated copy number variation (CNV), DNA methylation, mRNA and miRNA expression to identify the 5 HCC molecular subtypes from 256 TCGA samples 17 . However, most of these studies explored the molecular subtypes without relying on survival during the process of defining subtypes. Rather, survival information was used post hoc to evaluate the clinical significance of these subtypes 17 .
As a result, some molecular subtypes showed converging and similar survival profile, making them redundant subtypes in terms of survival differences 13 . New approaches to discover survival-sensitive and multi-omics data based molecular subtypes are much needed in HCC research.
To address these issues, for the first time, we have utilized deep learning (DL) computational framework on multi-omics HCC data sets. We chose autoencoder framework as the implementation of DL for multi-omics integration. Autoencoders have already been proved to be efficient approaches to produce features linked to clinical outcomes 18 . And it was successfully applied to analyze high-dimensional gene expression data 19, 20 , and to integrate heterogeneous data 21, 22 . Notably, autoencoder transformation tends to aggregate genes sharing similar pathways 23 , therefore making it appealing to interpret the biological functions. The contributions of this study to HCC field is not only manifested in its thorough and integrative computational rigor, but also unify the discordant molecular subtypes into robust subtypes that withstand the testing of various cohorts, even when they are in different omics forms. We derived the model from 360 HCC samples in TCGA multi-omics cohort, which have mRNA expression, miRNA expression, CpG methylation and clinical information. We discovered two subtypes with significant differences in survival. These subtypes hold independent predictive values on patient survival, apart from clinical characteristics. Most importantly, the two subtypes obtained from our DL framework are successfully validated in five independent cohorts, which have miRNA or mRNA or DNA methylation results. Functional analysis of these two subtypes identified that gene expression signatures (KIRT19, EPCAM and BIRC5) and Wnt signaling pathways are highly associated with poor survival. In summary, the survival-sensitive subtypes model reported here is significant for both HCC prognosis prediction and therapeutic intervention.
Results

Two differential survival subtypes are identified in TCGA multi-omics HCC data
From the TCGA HCC project, we obtained 360 tumor samples that had coupled RNA-seq, miRNA-seq and DNA methylation data. For these 360 samples, we pre-processed the data as described in the 'Materials and Methods' section, and obtained 15,629 genes from RNA-seq, 365 miRNAs from miRNA-seq, and 19,883 genes from DNA methylation data as input features. These three types of omics features were stacked together using autoencoder, a deep learning framework 24 . The architecture of autoencoder is shown in Figure 1A . It has 5 layers of nodes: an input layer, a hidden layer for encoding, a bottleneck layer, a hidden layer for decoding, and an output layer. We used tanh function for activation and retrieved 100 new transformed features from the bottleneck layer. We then conducted univariate Cox-PH regression on each of the 100 features, and identified 37 features significantly (log-rank p-value <0.05) associated with survival. These 37 features were subjective to Kmeans clustering, with cluster number K ranging from 2 to 6 ( Figure 1B ). Using silhouette index and the Calinski-Harabasz criterion, we found that K=2 was the optimum with the best scores for both metrics ( Supplementary Fig. 1A ). Further, the survival analysis on the full TCGA HCC data shows that the survivals in the two sub-clusters are drastically different (log-rank p-value =7.13e-6, Figure 2A ). Moreover, K=2 to 6 yielded KM survival curves that essentially represent 2 significantly different survival groups ( Supplementary Fig. 1B ).
Thus, we determined that K=2 was the classification labels for the subsequent supervised machine learning processes.
We next used the 2 classes determined above as the labels to build a classification model using the support vector machine (SVM) algorithm with cross-validation (CV) (Fig. 1B) . We split the 360 TCGA samples into 10 folds using 60/40 ratio for training and testing data. We chose 60/40 split, rather than a conventional 90/10 split, in order to have sufficient testing samples for sensible log-rank p-values in the survival analysis (see 'Materials and Methods'). Additionally, we assessed the accuracy of the survival subtype predictions using C-index, which measures the fraction of all pairs of individuals whose predicted survival times are ordered correctly 25 . We also calculated the error of the model fitting on survival data using Brier score 26 . On average, the training data generated high C-index (0.70±0.04), low brier score (0.19±0.01), and significant average log-rank p-value (0.001) on survival difference (Table 1) . Similar trend was observed for the 3-omics held-out testing data, with C-index=0.69±0.08, Brier score=0.20±0.02, and average survival p-value=0.005 (Table 1) . When tested on each single omic layer of data, this multi-omics model also has decent performances, in terms of C-index, low Brier scores and log-rank p-values (Table 1 ). These results demonstrate that the classification model using cluster labels is robust to predict survival-specific clusters.
The performance of the model described in Fig. 1B is superior to the alternative model, where autoencoder is replaced by traditional dimension reduction approach namely Principal Component Analysis (PCA). The PCA approach failed to give significant log-rank p-value (α=0.05) in survival subgroups. It also yielded significantly lower C-indices for both the training (0.63, p-value<0.01) and testing (0.62, p-value < 0.05) data ( Supplementary   Table 1 ), as compared to the model using autoencoder. Worth noticing, the 3-omics based DL model gives better prediction metrics in CV, when compared to single-omics based DL models (Supplementary Table 2 ), suggesting that indeed multi-omics data are better than single-omics data for model building.
The survival subtypes are robustly validated in five independent cohorts
To demonstrate the robustness of the classification model at predicting survival outcomes, we validated the model on a variety of five independent cohorts, each of which had only mRNA, or miRNA or methylation omics data ( Table 2 and Fig. 2 B-F). LIRI-JP dataset is the RNA-seq data set with the most number of patients (n=230); we achieved a good C-index 0.75, a low Brier error rate of 0.16 and the log-rank p-values of 4.4e-4 between the two subtypes. For the second largest (n=221) NCI cohort (GSE14520), the two subgroups have decent C-index of 0.67 and low Brier error rate of 0.18 with log-rank p-value of 1.05e-3 ( Table 2 ). For Chinese cohort (GSE31384), the miRNA array data with 166 samples, the two subgroups have C-index of 0.69, low Brier error rate of 0.21, and log-rank p-value of 8.49e-4 ( Table 2 ). Impressively, the C-indices for the two smallest 
Adding clinical information does not improve DL-based multi-omics model
It remains to see if the DL based multi-omics model will improve the predictability, by adding clinical information. Therefore, we assessed the performance of alternative models with clinical variables as the features, either alone or in combination with previous DL-based multi-omics model ( Table 3) . When clinical features were used as the sole feature set for survival prediction, the models' performances were much poorer (Table 3) , when compared to the DL-based genomic model ( Table 2 ). Then we combined the clinical features with the 3 omics layers before the k-means clustering step in Fig. 1B . Surprisingly, the C-indices of the combined model were not better on the validation cohorts with larger sample sizes (LIRI-JP, NCI and E-TABM-36 cohorts), compared to those of DL-based multi-omics model. C-index and p-value were only slightly but not statistically significantly better for the Hawaiian cohort, which has only 27 samples. We thus conclude that the DL-based multi-omics model performs sufficiently well even without clinical features. We speculate the reason is due to the unique advantage of DL neural network, which can capture the redundant contributions of clinical features through their correlated genomic features.
Associations of survival-subgroups with clinical covariates
We performed the Fisher's exact test between the two survival subgroups and the clinical variables from TCGA cohort, and found that only grade (P=0.0004) and stage (P=0.002) were significantly associated with survival, as expected. Since HCC is aggravated by the multiple risk factors including HBC, HCV, and alcohol, we also tested our model within subpopulations stratified by individual risk factors (Table 4) . Impressively, our model performed very well on all the risk factor categories with C-indices ranging from 0.69-0.79, and Brier scores between 0.19 and 0.20. Log-rank P-values were significant in HBV infected patients (P=0.04), alcohol consumers (P=0.005) and other category (P=0.0035). The only non-significant p-value (P=0.20) was obtained from the HCV infected patients, probably attributed to the small group size (n=31).
TP53 is one of the most frequently mutated genes in HCC, and its inactivation mutations have been reported to be associated with poor survival in the HCC 27 . Between the 2 survival subgroups S1 and S2 in TCGA samples, TP53 is more frequently mutated in the aggressive subtype S1 (Fisher's test p-value=0.042). Further, TP53 inactivation mutations are associated with the aggressive subtype S1 in LIRI-JP cohort, where whole genome sequencing data are available (p-value=0.024).
Functional analysis of the survival-subgroups in TCGA HCC samples
We used DESeq2 package 28 for differential gene expression between the two identified subtypes. After applying the filter of log2 fold change >1 and FDR <0.05, we obtained 820 up-regulated and 530 down-regulated genes in the aggressive sub-cluster S1. Fig. 3 shows the comparative expression profile of these 1350 genes after normalization. The up-regulated genes in the S1 cluster include the stemness marker gene, EPCAM (P=5.7e-6), KRT19 (P=6.7e-15) and tumor marker BIRC5 (P=1.2e-13) genes, which were also reported earlier to be associated with aggressive HCC subtype [29] [30] [31] . Additionally, 18 genes (ADH1B, ALDOA, APOC3, CYP4F12, EPHX2, KHK, PFKFB3, PKLR, PLG, RGN, RGS2, RNASE4, SERPINC1, SLC22A7, SLC2A2, SPHK1, SULT2A1, TM4SF1) differentially expressed in the two subtypes have similar trends of expression as in the previous study, where a panel of 65-gene signature was associated with the HCC survival 32 .
Using the differentially expressed genes above, we conducted KEGG pathway analysis to pinpoint the pathways enriched in two subtypes. These subtypes have different and (almost) disjoint active pathways, confirming that they are distinct subgroups at the pathway level ( Fig. 4) . Aggressive subtype S1 is enriched with cancer related pathways, Wnt signaling pathway, PI3K-Akt signaling pathway etc. (Fig. 4A ). Wnt signaling pathway was reported being associated with aggressive HCC previously 33 . In contrast, the moderate subtype S2 has activated metabolism related pathways including drug metabolism, amino acid and fatty acid metabolism etc. (Fig. 4B ). We performed similar differential analysis for miRNA expression and methylation data, and detected 23 miRNAs and 55 genes' methylation statistically different between the two subgroups ( Supplementary Fig. 2 and File 1).
Discussion
Heterogeneity is one of the bottlenecks for understanding the HCC etiology. Though there are many studies for subtype identification of the HCC patients, embedding survival outcome of the patients as part of the procedure of identified subtypes has not been reported before. Moreover, most reported HCC subtype models have either no or very few external validation cohorts. This calls for better strategies, where the identified subtypes could reflect the phenotypic outcome of the patients i.e. the survival directly. Present work includes the integration of the multi-omics data from the same patients, giving an edge by exploiting the improved signal-to-noise ratio. To our knowledge, we are the first to use the deep learning framework to integrate multi-omics information in HCC.
It propels deep learning to develop risk stratification model, not only for prognostication but also instrumental for improvising risk-adapted therapy in HCC.
We have identified two subtypes from the molecular level. This model is robust and perhaps more superior than other approaches, manifested in several levels. First, CV results gave the consistent performance in TCGA HCC testing samples, implying the reliability and robustness of the model. Secondly, deep-learning technique used in the model has captured sufficient variations due to potential clinical confounders, such that it performs as accurately or even better than, having additional clinical features in the model. Thirdly, autoencoder framework has much more efficiency to infer features linked to survival, compared to PCA. Lastly and most importantly, this model is repetitively validated in five additional cohorts, ranging from RNA-seq, mRNA microarray, miRNA array, and DNA methylation platforms.
In association with clinical characteristics, the more aggressive subtype (S1) has consistent trends of association with higher TP53 inactivation mutation frequencies in the TCGA and LIRI-JP cohorts, which is in concordance with the previous study 27 . Association of stemness markers (KRT19, EPCAM) with S1 subtype is also in congruence with the literature 29, 30 . Moreover, S1 subtype is enriched with activated Wnt signaling pathway 33 .
Despite our effort, the one to one comparison with the previous studies is not feasible due to the absence of cluster label information in original reports, and lack of survival data in some cases. Fortunately, we were able to identify five external validation cohorts encompassing different omic dataset, and succeeded in validating the subtypes among them. These results gave enough confidence that the 2 survival subtype model proposed in this report is of direct clinical importance, and maybe useful to improve HCC patients survival. Validation dataset 4 (E-TABM-36-microarray gene expression): 40 HCC samples were used, with survival information and transcriptional profiling from Affymetrix HG-U133A GeneChips arrays platform 13 . We used the CHPSignal values for the further processing as a measure of gene expression.
Methods
Datasets
Validation dataset 5 (DNA Methylation): 27 samples were used, with genome-wide methylation profiling from Illumina HumanMethylation450 BeadChip platform 40 . Probe to gene conversion was done the same way as for TCGA HCC methylation data. Supplementary Table 3 .
All the available clinical information for the validation cohorts is listed in
Deep Learning framework
We used the 3 pre-processed TCGA HCC omics data sets as the input for the autoencoders framework. We stacked the 3 matrices that are unit-norm scaled by sample, in order to form a unique matrix as reported before 41 .
An autoencoder is a feedforward, non-recurrent neural network 24 . Given an input layer x, the objective of an autoencoder is to reconstruct x by the output layer x' (x and x' have the same dimension), via transforming x through successive hidden layers. For a given layer i, we used tanh as activation function between input layer x and output layer y. That is:
Where W i is the coefficient matrix and b i the intercept. For an autoencoder with k layers, x' is then given by:
We chose logloss as objective function:
In order to control overfitting, we added a L1 regularization penalty on the coefficient weight W i , and a L2 regularization penalty on the hidden nodes activities:
. Thus the objective function to minimize becomes:
New feature selection and K-means clustering
We used the bottleneck layer of the autoencoder to select features linked to survival. For each node of this layer,
we computed the activity of the node for every sample from the training set and built a Cox-PH model using the survival data. We selected nodes from which a significant Cox-PH model is obtained (log-rank p-value < 0.05).
We then used these new features to cluster the samples using the k-means clustering algorithm. We determined the optimal number of clusters with two metrics: Silhouette index 42 and Calinski-Harabasz criterion 43 . We used the scikit-learn package as the K-Means implementation 44 .
Supervised classification
Using the labels obtained from K-means clustering, we built a supervised classification model using Support
Vector machine (SVM) algorithm. We first selected common features between the training and the validation datasets. We then applied robust-scaling on the validation dataset, using the means and the standard deviations of the training dataset 45 . Finally, we selected the top N features which are most correlated with the cluster labels, using ANOVA F-values. We set default N values as 200 for mRNAs, 200 for methylation and 50 for miRNAs.
We used grid search approach to find the best hyperparameters of the SVM classifier, using 5-fold CV for each set of parameters. We used the scikit-learn package to build the SVM models, perform the grid search and compute the ANOVA 44 .
Robustness assessment
We performed robustness assessment using a CV like procedure. We used a 60/40% split (training/test sets) of the TCGA data, in order to have sufficient number of test samples that generate evaluation metrics. We first randomly split the 360 samples from TCGA into 5 folds and used each pair of folds as a new fold (40% of the data), thus obtaining 10 new folds. For each fold, we constructed a model using the 60% remaining samples and predicted the labels for the sample from the fold.
Evaluation metrics for models
The metrics used closely reflects the accuracy of survival prediction in the subgroups identified. Three sets of evaluation metrics were used.
Concordance index (C-index):
The c-index can be seen as the fraction of all pairs of individuals whose predicted survival times are correctly ordered 25 and is based on Harrel's C statistics 46 . A C-index score around 0.70 indicates a good model, whereas a score around 0.50 means random background.
To compute the c-index, we first built a Cox-PH model using the training dataset (cluster labels and survival data) and predict survival using the labels of the test/validation dataset. We then calculated the concordance index (c-index) using function concordance.index in R survcomp package 47 . To compute the C-index using the multiple clinical features, we built a Cox-PH using the glmnet package 48 instead, which enables penalization through ridge regression. Before building the Cox-PH model, we performed a 10-fold cross-validation to find the best lambda.
Log-rank p-value of Cox-PH regression:
We plotted the Kaplan-Meier survival curves of the two risk groups, and calculated the log-rank p-value of the survival difference between them. We used Cox proportional hazards (Cox-PH) model for survival analysis 49 , similar to described before 50,51 , using R survival package 52 Brier score: It is another score function that measures the accuracy of probabilistic prediction 26 . In survival analysis, the brier score measures the mean of the difference between the observed and the estimated survival beyond a certain time 53 . The score ranges between 0 and 1 and a larger score indicates higher inaccuracy. We used the implementation of Brier score from R survcomp package.
Functional analysis
A number of functional analyses were performed to understand the characteristics of 2 survival risk subtypes of TCGA HCC samples. 
Differential Expression:
In order to identify the differential expressed genes between the two survival risk subtypes, we performed the differential expression analysis for the mRNA, miRNA expression and methylation genes. We used DESeq2 package 28 to identify the differential gene and miRNA expression between the 2 subtypes (false discovery rate, or FDR <0.05). Additionally, we used log2 fold change greater than 1 as filtering for mRNA/miRNA. For methylation data, we transformed the beta values into M values as elsewhere 54, 55 using the lumi package in R 56 . We fit the linear model for each gene using lmFit function followed by empirical Bayes method, using limma package in R 57 . It uses moderate t-tests to determine significant difference in methylation for each gene between S1 and S2 subtypes (Benjamin-Hochberg corrected P<0.05). Additionally, we used averaged M value differences greater than 1 as filtering. We used volcano plot to show the differentially methylated genes in two subtypes.
Enriched pathway analysis: We used upregulated and downregulated genes for the KEGG pathway analysis, using the functional annotation tool from the online DAVID interface 58, 59 . We used a p-value threshold of 0.10 to consider a pathway significant. We plot the gene-pathway network using Gephi 60 . Enriched pathway-gene analysis for upregulated genes in the (A) S1 aggressive tumor sub-group and (B) less aggressive S2 sub-group. 
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